Monte Rosa: MRT-2359 dose update; MRT-6160 IND for autoimmune diseases

Monte Rosa Therapeutics, Inc.

MRT-2359 Phase 1/2: favorable safety at 0.5 mg 21/7 schedule; evaluating 0.75 mg cohort; RP2D and updated data expected H2 2024.
IND submitted for MRT-6160, VAV1-directed MGD for systemic/neurological autoimmune diseases; Phase 1 SAD/MAD starts summer 2024 with data Q1 2025.
MRT-2359 potential RP2D of 0.5 mg using 21 days on/7 days off regimen, allowing twice as frequent dosing per cycle vs prior schedule.
MRT-6160 is first rationally designed MGD for non-oncology indication; preclinical efficacy in IBD, RA, MS models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.